CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...

By the time doctors began properly treating E.S.’s HIV, “it was super late.” The disease had progressed to AIDS at that point ...

The Supreme Court said Friday it will review the constitutionality of the Affordable Care Act’s no-cost coverage mandates for ...

The government provides HIV medicines free of charge. Yet in one indigenous territory, cases and deaths are increasing at an ...

Drought and heavy rainfall also increased the risk of HIV and sexually transmitted infections (STIs), particularly among ...

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

A Mountain View barber on the run after being accused of sexual assaults is believed to have HIV, Santa Clara County ...

For years, John Fleischman carried the journal of his late mentor, who died from HIV/AIDS. He finally found the perfect home ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

In addition to having more space and privacy for patients, Ireland said the new location presents a chance for the HOPE ...

People living with HIV in California were highly satisfied with telephone visits during the height of the COVID-19 pandemic ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...